Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer

Fig. 3

Mendelian randomization estimates of the associations between inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with prostate cancer among men. HMG-CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A Reductase; NPC1L1, Niemann-Pick C1-Like 1; PCSK9, proprotein convertase subtilisin/kexin type 9; CI, confidence interval. An observed 2-sided P < 0.008 (Bonferroni-correction significance threshold calculated as 0.05 divided by 6 [3 drug targets against 2 outcomes]) was considered to be statistically significant

Back to article page